SWAN-PSMA-1007, September 2019
Swissmedic has granted SWAN Isotopen AG a temporary market approval for SWAN-PSMA-1007.
The product is a radiodiagnostic used, by PET imaging, to visualize the increased expression of prostate specific membrane antigen (PSMA). It can be used to detect tumors in patients suffering from adenocarcinoma of the prostate gland (Prostate cancer).
